

NOAP Research Committee Meeting Minutes

April 12, 2023 Occurs 2rd Wednesday of the month

Agenda

- 1. Roll call:
 - John Furman present
 - Maureen Farrell present
 - Abby Migliore present
 - Mike Harkreader present
 - Shannon Opie present
- 2. March meeting minutes approved as written.
- 3. Newly Published:

Choflet, A., et al (2023). Accessibility and Financial Barriers in the Utilization of Alternative to discipline Programs in the United States. Online Journal of Issues in Nursing. (attached)

4. Suggested Paper of the Month:

Smith, A.M., and Campbell, D.G. (2020). *Strategies to Address Substance-Abusing and Substance-Impaired healthcare Professionals*. International Journal of Applied Management & Technology. (attached)

- 5. Standard performance measures project:
 - Discussion regarding the mission of regulatory monitoring/health programs and how to core functions (i.e., patient safety, early identification and referral to treatment, retention, return to practice, advocacy).

Action:

- John will review available program mission statements and construct the next panel survey to connect measures with common core mission functions.
- John will provide an update during the NOAP Conference Business Meeting.
- 6. New research questions/projects for consideration:
 - Are "secular" meetings as effective as traditional 12 step meetings?
 - Is there a correlation between reported increased use/sales of alcohol and SUD statistics since COVID-19?
 - Is Vivitrol therapy as effective in reducing relapse and supporting retention in clinical positions as traditional clinical and regulatory (i.e., license inactivation, practice restrictions) interventions?
 - Comparison of treatment modalities vs an initial license inactivation approach in regard to overall compliance and success rates (completion, no relapses in monitoring, etc.). What are best treatment practices for clinicians with SUD?
 - What are the current state employer policies that address SUD and that support nurses returning to practice e.g., medical leave of absence for treatment, accommodations for nurses who have narcotic access restrictions?
 - What are the outcomes for nurses who are arrested and charged for diversion vs. nurses that have no legal consequences?
 - How do states without ATD programs compare with those who do in regard to the management and outcomes for clinicians with SUD?
 - How do state statutes regarding clinicians with SUD compare?
 - Are there best treatment practices for clinicians with SUD?

Action: To discuss with the NOAP Board and revisit during the June Research Committee meeting.

7. Government Affairs:

• FDA Approves Narcan nasal spray for OTC use <u>FDA Approves First Over-the-Counter</u> Naloxone Nasal Spray | FDA

8. Old Business:

• The May Research Committee meeting will be held during the Thursday May 18 lunch period.

9. New Business:

• Sheron Russell has resigned from the committee. We will recruit for a replacement